Monday, July 23, 2018
 
 
Company News: Page (1) of 1 - 07/12/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Gala Therapeutics Receives FDA IDE Approval for a US Early Feasibility Study of Its RheOx™ System to Treat Chronic Bronchitis
 
(July 12, 2018)

MENLO PARK, Calif., July 12, 2018 /PRNewswire/ -- Gala Therapeutics (Gala) today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to conduct an Early Feasibility Study (EFS) to examine the safety of the RheOx™ system in subjects with Chronic Bronchitis.  The study will enroll up to 15 patients at 5 clinical trial sites in the United States.

"Patients with Chronic Bronchitis suffer daily with mucus hypersecretion and cough," stated Jonathan Waldstreicher, MD, Chief Executive Officer of Gala.  "We developed the Bronchial Rheoplasty™ procedure to directly treat the abnormal airway cells responsible for Chronic Bronchitis, which are not impacted by inhaled medications.  We appreciate the FDA's commitment to encouraging clinical development of medical devices in the United States through the EFS process."

"In our early clinical work outside of the United States, we have demonstrated the safety and profound impact of Bronchial Rheoplasty™ in relieving chronic cough and mucus production, which has been confirmed with other objective measures of improvement," commented Bill Krimsky, MD, Chief Medical Officer of Gala.  "As a pulmonologist, I see these patients daily.  We are now one step closer to offering them an outpatient minimally-invasive procedure to alter the usual downward spiral of this disease, which could become first-line therapy."



Gala Therapeutics is the first company to bring an interventional pulmonary procedure targeting Chronic Bronchitis to the United States.  A form of COPD, the Centers for Disease Control and Prevention (CDC) estimates that 8.94 million patients in the United States are diagnosed with Chronic Bronchitis, defined as chronic inflammation of the airways associated with over-production of mucus.  Risk factors for Chronic Bronchitis include smoking, vaping, secondhand smoke, exposure to airborne chemicals, pollution and other irritants.  RheOx™ is under clinical investigation and not available for sale or distribution.

About Gala Therapeutics

Gala Therapeutics is a privately-held medical device company based in Menlo Park, CA that was formed by Apple Tree Partners, a healthcare-focused venture capital firm based in New York. Gala is dedicated to developing disease modifying therapies that improve survival, quality of life, and outcomes for patients with lung cancer, COPD, asthma, and other pulmonary diseases. Gala is building a portfolio of technologies to address the needs of interventional pulmonologists, thoracic surgeons, and all physicians who treat pulmonary disease.

Cision View original content:http://www.prnewswire.com/news-releases/gala-therapeutics-receives-fda-ide-approval-for-a-us-early-feasibility-study-of-its-rheox-system-to-treat-chronic-bronchitis-300680218.html

SOURCE Gala Therapeutics, Inc.

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


Related Keywords:USA,Medicine,Disease,Cancer,Technology,Surgery,Children,Medical Technology,Other,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Healthcare IT Market 2018 - 2023 with SWOT Analysis regarding upcoming Changes and Technology Adaptations in Global Healthcare Sector
  • Vision Care Product Market To Witness Enhanced Growth Owing To Rising Occurrence Of Eye Disorders Till 2021 | Million Insights
  • Global Prosthetic Heart Valve Market Reaching at a CAGR of +12.70% by Geography, Deployment Model, Component, and Key players are Boston Scientific Cardiology, CryoLife, Inc., Abbott
  • Trauma Fixation Global Market to Register Steady Expansion During 2018-2025
  • Global Surgical Apparel Market Will Reach USD 2,966.58 million by 2024: Zion Market Research

    Cancer
  • CStone Pharmaceuticals Appoints Former Goldman Sachs Executive Richard Yeh as CFO
  • HedgePath Pharmaceuticals Granted Exclusive Option to License UCONN's Patented Chemical Analogues of Itraconazole
  • Alligator Bioscience Submits Application to Start Clinical Phase I Study in Cancer Patients with ATOR-1015, a Unique CTLA-4 and OX40 Binding Antibody
  • Yisheng Biopharma Announces Opening of New Business Divisions in Cambodia, Expanding Presence within Southeast Asia
  • Mesothelioma is a Deadly Cancer and it’s Completely Preventable
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines